Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients
| Autor: | J. Marina Maurer, Peter Nieboer, C. H. Mom, Elisabeth G.E. de Vries, A. N.Mac Hteld Wymenga, H. Marike Boezen, Robert S. De Jong, Pax H.B. Willemse, Marian J.E. Mourits, Ciska Buijs |
|---|---|
| Přispěvatelé: | Obstetrics and gynaecology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, Amsterdam Reproduction & Development (AR&D), Faculteit Medische Wetenschappen/UMCG, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Life Course Epidemiology (LCE), Targeted Gynaecologic Oncology (TARGON), Groningen Research Institute for Asthma and COPD (GRIAC), Guided Treatment in Optimal Selected Cancer Patients (GUTS) |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Cancer Research Randomization Sexual Behavior ADJUVANT TAMOXIFEN Venlafaxine Hydrochloride DISCONTINUATION Venlafaxine Breast Neoplasms CONTROLLED-TRIAL Clonidine INDUCED SEXUAL DYSFUNCTION law.invention REPLACEMENT THERAPY Breast cancer Randomized controlled trial Double-Blind Method law medicine MANAGEMENT Humans HYDROCHLORIDE Hot flashes SURVIVORS Cross-Over Studies business.industry Middle Aged CHEMOTHERAPY medicine.disease Cyclohexanols Crossover study Discontinuation Menopause Treatment Outcome Oncology POSTMENOPAUSAL WOMEN Anesthesia Quality of Life Female business Adrenergic alpha-Agonists Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Breast Cancer Research and Treatment, 115(3), 573-580. Springer New York Buijs, C, Mom, C H, Willemse, P H B, Marike Boezen, H, Maurer, J M, Wymenga, A N M H, De Jong, R S, Nieboer, P, De Vries, E G E & Mourits, M J E 2009, ' Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients : A double-blind, randomized cross-over study ', Breast Cancer Research and Treatment, vol. 115, no. 3, pp. 573-580 . https://doi.org/10.1007/s10549-008-0138-7 Breast Cancer Research and Treatment, 115(3), 573-580. SPRINGER |
| ISSN: | 0167-6806 |
| DOI: | 10.1007/s10549-008-0138-7 |
| Popis: | Purpose Breast cancer patients with treatment-induced menopause experience frequent and severe hot flashes (HF). We compared venlafaxine and clonidine for the treatment of HF with regard to side effects, efficacy, quality of life and sexual functioning. Methods In a double-blind, cross-over study, 60 breast cancer patients experiencing HF were randomized to 8 weeks venlafaxine followed by 2 weeks wash-out, and 8 weeks clonidine or vice versa. HF frequency and severity, side effects, quality of life and sexuality were assessed. Results Thirty patients started with venlafaxine and 30 with clonidine. Premature discontinuation for toxicity occurred in 14/59 during venlafaxine and 5/53 during clonidine (P = .038). Venlafaxine induced more side effects. Median reduction in HF score was 49% for venlafaxine and 55% for clonidine (ns). Conclusion Venlafaxine and clonidine are equally, but moderately effective in HF reduction. Side effects are the main reason for drug discontinuation, occurring more often with venlafaxine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink